These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25817631)

  • 1. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic.
    Patricio CM; Gabriela C; Julieta RM; Marcos FS; Federico N; Griselda R; Claudio W; Santiago P; Leonardo T; Jorge C; Alejandra A; Janus K; Salvador G; Ramon L; Gustavo S; Silvia V; Ricardo A
    Am J Alzheimers Dis Other Demen; 2015 Sep; 30(6):599-606. PubMed ID: 25817631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.
    Ng SY; Villemagne VL; Masters CL; Rowe CC
    Arch Neurol; 2007 Aug; 64(8):1140-4. PubMed ID: 17698704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
    Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
    Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.
    Rabinovici GD; Jagust WJ; Furst AJ; Ogar JM; Racine CA; Mormino EC; O'Neil JP; Lal RA; Dronkers NF; Miller BL; Gorno-Tempini ML
    Ann Neurol; 2008 Oct; 64(4):388-401. PubMed ID: 18991338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia.
    Santos-Santos MA; Rabinovici GD; Iaccarino L; Ayakta N; Tammewar G; Lobach I; Henry ML; Hubbard I; Mandelli ML; Spinelli E; Miller ZA; Pressman PS; O'Neil JP; Ghosh P; Lazaris A; Meyer M; Watson C; Yoon SJ; Rosen HJ; Grinberg L; Seeley WW; Miller BL; Jagust WJ; Gorno-Tempini ML
    JAMA Neurol; 2018 Mar; 75(3):342-352. PubMed ID: 29309493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of
    La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting: A Visual and Semiquantitative Analysis.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Sánchez-Juan P; Carril JM
    Clin Nucl Med; 2016 Jan; 41(1):e18-23. PubMed ID: 26284764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment.
    Lee MJ; Seo SW; Na DL; Kim C; Park JH; Kim GH; Kim CH; Noh Y; Cho H; Kim HJ; Yoon CW; Ye BS; Chin J; Jeon S; Lee JM; Choe YS; Lee KH; Kim JS; Kim ST; Lee JH; Ewers M; Werring DJ; Weiner MW
    JAMA Psychiatry; 2014 Apr; 71(4):412-22. PubMed ID: 24554306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid deposition in semantic dementia: a positron emission tomography study.
    Brown EE; Graff-Guerrero A; Houle S; Mizrahi R; Wilson AA; Pollock BG; Mulsant BH; Felsky D; Voineskos AN; Tang-Wai DF; Verhoeff NP; Freedman M; Ismail Z; Chow TW
    Int J Geriatr Psychiatry; 2016 Sep; 31(9):1064-74. PubMed ID: 26807731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.